Genesis Therapeutics

What is Genesis Therapeutics?

Genesis Therapeutics is an AI-driven platform designed to speed up the discovery of new medicines. It focuses on identifying new protein targets and exploring uncharted chemical possibilities to bring new treatments to people faster. The company uses advanced molecular AI, including 3D spatial graph modeling and molecular simulation, to create promising drug candidates.

Its team combines experienced drug hunters, deep learning experts, and software engineers working to advance AI in biochemistry and develop therapies for serious illnesses. Genesis Therapeutics has attracted notable investors, including Andreessen, contributing to a $200 million funding round, and has partnered with major industry players such as Eli Lilly, Roche, and Genentech to strengthen its drug discovery efforts.

Who created Genesis Therapeutics?

Genesis Therapeutics was founded on October 27, 2019 by a team of drug hunters, deep learning researchers, and software engineers. The company’s core focus is applying advanced molecular AI to pinpoint new protein targets, explore unexplored chemical areas, and accelerate the development of new medicines.

What is Genesis Therapeutics used for?

• Finding previously unidentified protein targets
• Exploring uncharted chemical possibilities
• Speeding up the development of new medicines
• Applying 3D spatial graph modeling and molecular simulation techniques
• Practical applications in biochemistry
• Partnerships and collaborations with industry leaders, including Eli Lilly and Genentech

Who is Genesis Therapeutics for?

• Drug discovery professionals
• Deep learning researchers
• Software engineers

Key facts

• Founded: October 27, 2019
• Funding: $200 million funding round, with investment from Andreessen
• Partnerships: Eli Lilly, Roche, and Genentech
• Core technology: Molecular AI, including 3D spatial graph modeling and molecular simulation
• Mission: Apply AI in biochemistry to discover therapies for serious disorders